
Common Antidepressant Slashes Risk of COVID Death
Fluvoxamine is both inexpensive and highly effective at preventing mild COVID-19 from turning severe

Fluvoxamine is both inexpensive and highly effective at preventing mild COVID-19 from turning severe

This Covid question played out long ago, in the fight against smallpox in 1872

As U.S. Food and Drug Administration advisers recommend authorizing shots for children aged five to 11, researchers predict what this might mean for populations

A new book reveals how quiet scientists, big drug companies and the Trump administration raced to meet the COVID threat—and why kids are just now being considered for shots

Companies are updating vaccines and testing them on people to prepare for whatever comes next in the pandemic

Today we bring you a new episode in our podcast series COVID, Quickly. Every two weeks, Scientific American ’s senior health editors Tanya Lewis and Josh Fischman catch you up on the essential developments in the pandemic: from vaccines to new variants and everything in between...

Now that the FDA has authorized the shots for a broad range of Americans, many people want to know if they need a booster dose. Here’s what we have learned so far

The WHO-approved RTS,S vaccine has a modest efficacy and requires a complex regimen of doses, so ample funding and clear communication are crucial to success

Studies show the vaccines against the disease not only can be safely given to people who are expecting but can also save lives

The number of pregnant people suffering from severe COVID is preventable tragedy

The actual number who resign rather than get the vaccine is much smaller than the survey data suggest

Pfizer expects to have safety and efficacy data on five- to 11-year-olds by the end of the month, but federal authorities must still review it

Standard remedies offer little relief for the itchy rash caused by the plant, but researchers have found promising clues in the immune system

The risk of severe disease dropped by factor of almost 20 in people over 60—but some dispute the benefits of offering an additional dose

Fewer than 0.5 percent of vaccine doses have been distributed to people living in low-income countries

Cases peaked, then fell, then rose again. “It is so much worse this time”

The plan includes vaccine mandates for federal workers and those at companies with 100 or more employees, but some experts say it doesn’t go far enough

Biochemist Katalin Karikó and her colleague Drew Weissman were recently awarded a $3-million Breakthrough Prize for their work

Pandemic ceasefires offer an opportunity to expand vaccination efforts, experts say. But negotiation is tricky

Their immune system is more primed to fight off the novel coronavirus
Support science journalism.

Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account